drug · small molecule
divarasib
Phase 3updated 6mo agoby Genentech Inc🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 2 investigational indications.
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying divarasib
- phase2A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- —An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
- phase3A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- phase1A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- phase3A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
- phase3A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- phase2Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- phase2A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
News(10)
- STAT+: RFK Jr. goes for broke in IowaKennedy on the campaign trail for MAHA, and new rules loom for U.S. investments in Chinese biotech.stat · 20d ago
- STAT+: Nonprofit resurrects shelved gene therapy after startup shuts downLast year, U.K. gene therapy startup Bloomsbury Genetic Therapies announced it was shutting down after dosing just one patient. Now, a nonprofit is resurrecting its lead program:stat · 20d ago
- A possible treatment for brain-eating amoebas, found in the seaBrain-eating amoebas are hard to treat and nearly always fatal. But researchers have isolated a compound that could help stop the disease.stat · 20d ago
- STAT+: Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its ownA small community tests if it can solve a crisis no one else could, for the simple reason that they have no other choice.stat · 21d ago
- Opinion: Cancer vaccines are finally here. How do we get them to patients?“If we want cancer vaccines to reach patients faster than BRCA testing did, there are several challenges to address now,” write Karen E. Knudsen and Othman Laraki.stat · 21d ago
- From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data dramaEvery ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly anticipated phase 3 data for Moderna and Merck & Co.’s cancer vaccine were leaked…fiercebiotech · 21d ago
- STAT+: Roche gets a lung cancer win with its KRAS drug divarasibOne of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which treats lung cancer.stat · 21d ago
- ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ dataAt one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.biopharma_dive · 21d ago
- STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and moreBristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trialstat · 21d ago
- ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivalsRoche has shed more light on its investigational KRAS G12C inhibitor’s phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati.fiercebiotech · 24d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that